Identify BTK-inh responder cohort to support label expansion

AI reveals responder cohorts to accelerate label expansion opportunities

Challenge

Third-in-class BTK inhibitor for lymphoma with low market share.

Solution

BostonGene identified responsive microenvironment subtypes to support label expansion, enabling studies, and targeted marketing strategies.
BostonGene reduced complexity and translate multiomics biomarker into blood-based biomarker using biological foundational model.